Lilly stock climbs on positive arthritis drug test
A potential rheumatoid arthritis treatment from drugmakers Eli Lilly and Co. and Incyte Corp. fared better than another drug in late-stage testing, Lilly said Tuesday.
Health Care & Life Sciences
Articles
Anthem says industry flush with competition, but local experts have doubts
After Anthem CEO Joe Swedish argued that his $54 billion purchase of Cigna Corp. wouldn’t harm competition, execs at some of Indiana’s most prominent health care and health insurance institutions expressed skepticism last week during the IBJ Health Care Power Breakfast.
Settlement clears way for Lilly to launch once-a-day insulin
The settlement with France-based Sanofi SA clears up uncertainty over a drug that could rack up more than $1 billion in sales by 2020, according to Wall Street analysts.
GOP wanted consumer-driven health care; Obamacare made it happen.
Since President Obama’s health law passed in 2010, deductibles on employer health plans have risen nearly seven times faster than wages and nearly three times faster than premiums, leaving consumers exposed more than ever to the sky-high cost of care.
Applications to Marian medical school keep rising
With the number of applications to Marian’s College of Osteopathic Medicine running twice as high as initially expected, school leaders say they are confident Marian can help reduce a looming physician shortage in Indiana.
Ball State trustees approve formation of College of Health
The new college's academic programs would include athletic training, nursing, speech pathology and psychology.
Clinton promises health insurance merger scrutiny in plan
Hillary Clinton said she would give close scrutiny to health-insurance industry mergers like those proposed this year by Anthem Inc. and Aetna Inc., part of the Democratic presidential candidate’s latest policy plans.
Purdue’s Chao Center regains drug, slashes $360-per-pill price
An Indiana not-for-profit has dropped the price of a drug for multi-drug resistant tuberculosis roughly 90 percent after re-acquiring rights to the medicine from Rodelis Therapeutics.
Anthem, Aetna defend acquisitions called harmful by hospitals
Anthem Inc. CEO Joseph Swedish and Aetna Inc. CEO Mark Bertolini will tell federal lawmakers Tuesday that the deals are necessary to succeed in a changing health-care landscape.
Analyst: Lilly’s Jardiance diabetes pill could be a $6 billion-a-year blockbuster
It looks like Eli Lilly and Co. finally has a drug that can replace its former stars Zyprexa and Cymbalta. The most bullish analysts think Jardiance can surpass those $5 billion-a-year blockbusters.
Lilly stock performs big despite analyst projections
Analysts have consistently given the Indianapolis-based company some of the lowest ratings among a group of 16 large drugmakers, but Lilly shares have been on a five-year rally.
American Senior Communities fires chief executive
The dismissal of James Burkhart as head of the Indianapolis-based nursing home company comes three days after FBI agents raided his Carmel home.
Lilly’s heart study sets up showdown with Novo’s Victoza
Unprecedented results from a cardiovascular study on a diabetes medicine sold by Eli Lilly and Co. turns up the pressure on rival Novo Nordisk, which will release data from a similar study on its competing drug next year.
Group urges Dems to tackle pharmaceutical prices
Pharmaceutical industry members are likely to dislike the proposal, which would require them disclose how much they spend on research and development, production, and sales and marketing.
Hospital-owned docs send more patients to lower-quality, higher-cost hospitals
When hospitals employ doctors—which is now the norm in central Indiana—more of those doctors’ patients end up going to hospitals with higher costs and poorer quality, according to a new study.
Jardiance study lifts Lilly shares to 15-year high
Eli Lilly shares soared Thursday after study results showed Jardiance sharply reduced chances of dying in diabetic patients at high risk of heart complications. The study prompted at least one analyst to predict the drug could bring in billions of dollars by the end of the decade.
Lilly shares jump on latest data from diabetes drug
A diabetes pill called Jardiance sold by Eli Lilly and Co. cut deaths from heart attacks and strokes in thousands of patients, the first drug to show promise in helping subdue two of the world’s most rampant health epidemics.
Senior health care firm operator Trilogy sold in $1.2B deal
Trilogy Health Services LLC, which operates more than 70 senior-living facilities in Indiana, is being acquired. The company has at least 14 properties in central Indiana, including two in Indianapolis.
Obamacare pumping more than $2B into Hoosier health insurers
A flood of money from Obamacare—for the expanded Healthy Indiana Plan and for private health insurance purchased on the federal exchange—is boosting revenue and profit among Indiana health insurers.
Drug-price increases slow as benefits managers get tough
A new analysis shows attempts by drugmakers to raise prices are being wiped out in negotiations with managers of drug insurance benefits like Express Scripts Holding Co. and CVS Health Corp.